|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.06 USD | +1.17% |
|
+0.25% | +16.04% |
Business description: Harmony Biosciences Holdings, Inc.
Number of employees: 268
Sales by Activity: Harmony Biosciences Holdings, Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Rare Neurological Diseases | 160M | 305M | 438M | 582M | 715M |
Geographical breakdown of sales: Harmony Biosciences Holdings, Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
United States (U.S.) | 160M | 305M | 438M | 582M | 715M |
Executive Committee: Harmony Biosciences Holdings, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Jeffrey Dayno
CEO | Chief Executive Officer | 67 | 2023-01-05 |
| Director of Finance/CFO | 55 | 2021-03-28 | |
Kumar Budur
CTO | Chief Tech/Sci/R&D Officer | 54 | 2024-04-30 |
Tricia Glover
CMP | Compliance Officer | - | - |
David Bradshaw
CTO | Chief Tech/Sci/R&D Officer | 63 | - |
Composition of the Board of Directors: Harmony Biosciences Holdings, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Jeffrey Aronin
CHM | Chairman | 57 | 2017-07-24 |
Antonio Gracias
BRD | Director/Board Member | 54 | 2017-08-31 |
Juan Sabater
BRD | Director/Board Member | 60 | 2016-12-31 |
Andreas Wicki
BRD | Director/Board Member | 66 | 2017-08-31 |
Jeffrey Dayno
BRD | Director/Board Member | 67 | 2023-04-23 |
Gary Sender
BRD | Director/Board Member | 63 | 2020-07-31 |
R. Graf
BRD | Director/Board Member | 60 | 2020-11-10 |
Linda Szyper
BRD | Director/Board Member | 59 | 2021-11-17 |
Peter Anastasiou
BRD | Director/Board Member | 54 | 2023-11-04 |
Ron Philip
BRD | Director/Board Member | - | 2025-04-06 |
Company details: Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc.
630 West Germantown Pike
19462, Plymouth Meeting
+
http://www.harmonybiosciences.com
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.21% | -0.65% | +24.20% | -34.08% | 2.28B | |
| +0.71% | +0.41% | +29.66% | +176.22% | 904B | |
| +0.14% | +4.33% | +44.06% | +18.46% | 506B | |
| -0.89% | -1.61% | +28.44% | +34.55% | 396B | |
| -0.58% | +1.67% | +23.72% | +4.32% | 342B | |
| -1.35% | -1.57% | +26.59% | +17.87% | 283B | |
| -0.40% | -1.31% | +20.01% | +24.43% | 256B | |
| +0.96% | +0.04% | -1.47% | -8.45% | 246B | |
| +0.50% | +3.88% | -59.01% | -29.54% | 223B | |
| +0.21% | -3.45% | +16.22% | +15.08% | 171B | |
| Average | -0.11% | +0.29% | +15.24% | +21.89% | 332.92B | |
| Weighted average by Cap. | -0.00% | +0.26% | +21.15% | +56.74% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HRMY Stock
- Company Harmony Biosciences Holdings, Inc.
Select your edition
All financial news and data tailored to specific country editions
